ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS. According to the protocol and statistical plan, reaching the target number of PFS events leads to completion of the blinded data collection process and then formal efficacy analysis by the IDMC (Independent Data Monitoring Committee). The Company will announce topline results from this trial during the last week of March 2013.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Actavis (ACT), Kissei Pharma Sue Sandoz, Hetero Over Rapaflo Patent
• Bristol-Myers (BMY), AstraZeneca (AZN) SAVOR-TIMI-53 Misses Primary Efficacy Endpoint in Phase 4
• MasterCard (MA), Western Union (WU) Launch Dedicated Int'l Payments Service for Business

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?